Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07639970 | Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors | not yet recruiting | Early Phase 1 | 20 | Hua PangOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07394205 |
| Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer |
| not yet recruiting |
| Early Phase 1 |
| 18 |
| First Affiliated Hospital of Wenzhou Medical UniversityOTHER |
| 1 |
| Feb 6, 2026 |
| clinicaltrials |
| NCT07026981 | [Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers | not yet recruiting | Early Phase 1 | 12 | Qiubai LiOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06645301 | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | not yet recruiting | Early Phase 1 | 15 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06196658 | Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | not yet recruiting | Early Phase 1 | 6 | Zhang Xiaofeng,MDOTHER | 0 | Jan 9, 2024 | clinicaltrials |
| NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | not yet recruiting | Early Phase 1 | 30 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials